METHOD AND AGENTS FOR ARRESTING FULMINATING INFECTION

Abstract: A method and associated agents for the arrest of infections resulting from organism growth in contact with an iron-containing body fluid, comprising administering an agent capable of immobilizing the body fluid so that the iron it contains is nutritionally unavailable for the organism. In the instance where the body fluid is blood, the agent may be administered in amounts effective to bind all of the available red blood cells or hemoglobin, to prevent breakdown of either and consequent release of iron to the organism. The agents preferably include materials capable of binding red blood cells and iron, such as haptoglobin, colloidal silica, anion exchange resins and mixtures thereof. Preferably, colloidal silica is used either alone or in a composite with a polyoflefin elastomer such as polyisobutylene. The agents may be coated on carriers or substrates, such as gauze pads, tampons and the like, and may be thus utilized topically, as well as intraperitoneally.

Description: MEIr-OD Z-2 ~~ AGZ-TTS FOR ARRESTING IXTECTIO BACKGROUND OF THE INVENTION Field of the Invention: The present invention relates to animal tissue infections, an particularly to methods and agents useful in their control and inhibition. Description of the Prior Art: The adverse patholog cal consequences of tissue trauma in humans and other animals, including the trauma induced by surgical procedures, has long been studied vπ ' th a view to preventing the development of bacterial infections that as a rule do not respond well to antibiotic therapy. In particular, trauma and bleeding in the peritoneum of humans, such as results during abdominal surgery, appears to foster the rapid growth of bacteria that cause fulminating infec- tions, that in the majority of cases, are fatal to the patien Experimental observations with animal models, suggest that the hemoglobin n blood is responsible for an acceleration in bacterial growth. In particular, the simultaneous intra peritoneal administration of hemoglobin and the bac¬ terium E . coli to mice resulted in a fulminating septicemia and rapid death that did not occur hen either the bacteria or the hemoglobin were individually adm nistered. Efforts to reduce the occurrence and severity of fulminating bacterial infections, have been limited to the curtailment of unwanted bleeding and the physical removal of unwanted blood from the peritoneal area , in conjunction with the administration of antibiotic therapy. Despite such measures, bacterial infections that de elop n this area continue to move rapidly out of control , and frequently are fatal to the patient. Bacterial nfections, and part cularly those that develop at the sight of tissue trauma, or at any " location where bleeding takes place have long been of concern, and, as such, the sub¬ ject of invest gation, for the purposes of developing pro¬ cedures for their control. Thus, whether topical or peritoneal in location, these bacterial infections frequently become fulminating in nature and can, in some instances result in death. SUMMARY OF THE INVENTION In accordance with the present invention, a method for arrest¬ ing organ sm-promoted animal tissue infection in the presence of iron-containing body fluid, comprises administering an agent capable of immobilizing the body fluid to make the iron nutri¬ tionally unavailable to the infection-promot ng organism. The present method may be used to make the red blood cells or the hemo globin fraction of free blood in the vicinity of a tissue trauma unavailable by infect on-promoting bacteria, so that the bac¬ teria cannot abstract the iron necessary for their growth. A wide variety of bacteria thrive on available iron, and range in ac¬ tivity from lethal, infection-causing varieties, to those that cause the evolution of undesirable odor during their life cycle. In a preferred embodiment, the agents of the present inventi are selected from colloidal silica, either alone or in combi tion with a supporting matrix, anionic exchange resins inclu ing cellulose-based resins, resins capable of binding to sul hydryl groups, plant lectins capable of binding with sugar, and exogenous haptoglobin. Preferably, the agent utilized comprises colloidal silica suspended in a matrix of polyiso- butylene. In the instance where the agent is administered to a periton tissue trauma, and the source of iron may include hemoglobin as well as heme or other iron salts, the agent may include haptoglobin in combination with other binding proteins, such as transferrin or he opexin, individually and in mixtures wi each other. In the instance where the agent is administered to a periton trauma, a sterile solution containing the agent may be prepa in a concentration that may range from about 1.0 to about 100 mg./ l. Admin stration may be either by direct dosage or by incorporation into conventional irrigation fluids. In the instance where topical treatments are contemplated, the agent must be disposed on the topical applicator or carrier in a manner such that the agent is available for surface contact with the blood or hemoglobin. Thus, for example, efforts to impregnate the agent into fibers and the like have been tried but with no success. The various agents useful in the present invention are widely available and are inexpensive to recover and ut lize, so that the present method may be widely practiced. In the instance where complex binding proteins are utilized a agents, they may either be derived from human plasma, or may be synthetically prepared. Such binding proteins are univers O — Δ— compatible with animal tissues and animal body fluids, so tha the risk of adverse reactions to thefr administration is non¬ existent. Accordingly, it is a principal object of the present inventio to provide a method for arresting bacterial infections that develop in the presence of body fluids offering available iro It is a further object of the present invention to provide a method as aforesaid that operates in rapid and complete fashi It is a yet further object of the present invention to provid a method as aforesaid that may utilize a variety of agents, in both topical and intraper toneal application. It is a still further object of the present invention to pro¬ vide agents and products carrying thse agents, for use in arresting bacterial infections. It is a still further object of the present invention to pre pare agents and products as aforesaid which are inexpensive to prepare and simple to use. Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing descri tion which proceeds with reference to the following illustra¬ tive drawings. BRIEF DESCRIPTION OF THE DRAWINGS FIGURES 1 and 2 graphically represent the results of in vitro comparative testing of the method of the present invention. FIGURES 3 and 4 graphically represent the results of in vivo testing of the method of the present invention. FIGURES 5 and 6 graphically represent the results of in vitr testing of the method of the present" invention , utilizing colloidal silica as the binding agent. DETAILED DESCRIPTION In accordance with the present invention, the method for arresting tissue infection in the presence of a body fluid containing iron accessible to the infection-promoting organi comprises administering to the locus of infection an agent capable of immobilizing the body fluid so that the iron is m nutritionally unavailable to the organisms. In the instance where the body fluid is blood, the agent is administered in an amount sufficient to immobilize either the red blood cell or the hemoglobin present in the blood adjacent the organisms The amount of the agent administered will therefore be pro- portional to the amount of the component of the blood sought to be im obi 1 ized. Agents useful in the immob lizat on of blood may be divided into two categories, depending upon the component of the blood for which immobil zation is desired. In the instance where it is desired to immobilize the red blood cell , the agents may comprise antibodies against the red blood cell, colloidal silica, anionic exchange resins, plant lectins cap¬ able of binding sugars, such as Concanavalin A, and other ma¬ terials known to aggregate red blood cells. In the instance where the component to be immobilized is hemoglobin, the agen may be selected from antibodies against hemoglobin, colloidal silica, anionic exchange resins, complexing proteins such as haptoglobin, and other materials having a known capability of binding hemoglobin. As discussed earlier, work previously done on this subject, has determined that bacterial organisms were capable of di¬ gesting the red blood cell and the hemoglobin, to abstract and adsorb the contained iron, to make it available for nu¬ trition and growth. In particular, Eaton et al., "Haptoglobi A Natural Bacteriostat" , SCIENCE, 215:591-692 (1982), summar¬ ized work performed on behalf and under the direction of the applicant and concerning the present invention, and restated the observations by earlier workers that the available iron abstracted from blood present in a wound, gave the bacteria sufficient nutrition to achieve rapid replication, so that the natural body defenses were inadequate to control the re¬ sulting fulminating infection. The -disclosure of the Eaton et al . article is incorporated herein by reference. The present invention relates to a method whereby a variety of agents may be utilized both peritoneally and topically, in amounts sufficient to bind either available red blood cell or avail abl e ■ hemogl obi n, and prevent either of the two from being broken down" by the undesired bacteria for the purpose of abstracting the iron contained therein. Under normal conditi-ons, the iron-containing fractions of blood are maintained secure against breakdown by association with certain complexing proteins. In particular, the fractio hemoglobin is secured by association with the protein hapto- globin, while the heme fraction is bound by the protein hemo- pexin, and iron occurring as iron salts is bound by the pro¬ tein transferrin. Each of the foregoing binding or complexin proteins, however, is present in relatively small amounts und normal circumstances. Increases of the levels of these prote can occur gradually, in response to the onset of certain in¬ ternal pathological conditions; however, the body is not equip c*.?ι to rapidly provide the relatively assive amounts of these proteins necessary to maintain iron n the unavailable se¬ questered state, such as in the instance where tissue trauma takes place and the blood is released from the vascular system into the peritoneum and thereby into contact with in¬ fection-promoting bacteria. Similarly, in the instance where natural release of blood takes place, or in the instance of topical abrasions and cuts, the quantity of blood released is frequently far in excess of the capability of these natural complexing agents. The difficulty engendered by this problem is apparent from a consideration that the red blood cells de¬ rived from 1 milliliter of blood can yield up to 150 milligrams of hemoglobin after red cell breakdown, a value that far exceeds the capacity of any haptoglobin normally present in that quantity of blood. In the instance where the agent comprises a complexing protein derived in exogenous form, it is preferably administered in a sterile solution. The quantity of agent may naturally vary, in relation to the nature and extent of body fluid liberated by the trauma. As the proteins haptoglobin, he opexin and trans- ferrin exist in human blood in amounts of approxiamtel 1.2 mg./ the quantities of such materials administered in accordance with the present method must naturally exceed these amounts sub¬ stantially, and generally varies in relation to the amount of body fluid released by the trauma, in a ratio with respect thereto ranging up to about 3 to 1. The ratio of the amount of agent administered with respect to body fluid released may preferably range from about 2 to 1 to about 3 to 1. Naturally, the foregoing proportions a re provided herein as illustrations only, both of the invention in general , and of a best mode of practice thereof. In instances therefore, where iron content ma vary, the proportion of the agent administered with respect to . body fluid released, may likewise differ, however such differ¬ ences are deemed to be within the scope of the present invention The agent is preferably utilized in conjunction with conven¬ tional antibiotic therapy, and provides the advantage of preventing the acceleration of bacterial growth that has rendered such therapy inadequate n the past. Bacterial growth generally occurs slowly during the initial 24 hours of inoculation, during which time growth is characterized by a lag phase. After this period is surpassed, accelerated or logarithmic growth commences, and full infection of the tissues become pronounced and ere . It has been found that control of the spread of bacterial infection can be achieved if growth during this initial 24 hour period can be either re¬ strained or reduced in rate. Accordingly, the present method proposes to administer rela¬ tively large amounts of agents capable of binding either the red blood cells or the hemoglobin component of the blood re¬ leased in any of these situations. Thus, in the instance of tissue trauma, due to surgical procedures or the like, a sterile solution containing the agent of the present invention may be directly administered by injection or otherwise, or may be incorporated in an irrigation fluid that is utilized to wash body wound areas. Additionall , the agent may be affixed to a surgical sponge which may then be utilized in con¬ tact with the blood. In the instance where the solutions of the agent are utilized, they may be prepared to concentrations of up to about 100 milligrams per millilitεr, and preferably from about 1.0 to about 100 milligrams per illiliter. Naturally, these quantities are illustrative only, and may vary in accord¬ ance with the present invention. In the instance where the agent is utilized for topical appli- cation, it may be disposed on various topical appliances, such as bandages and gauze pads, as well as sanitary and catamenial devices such as tampons. For example, in this latter instance, the agent may be disposed within a container in a tampon or within the pores of the absorbent material , as disclosed, re spectively, in U.S. Patent No. 3,842, " 166 to Bucalo and U.S. Patent No. 3,850,160 to Denson, cited herein as exemplary on In the instance where the present agents comprise colloidal silica, a particular form of colloidal silica is contemplate which is identified commercially as "Cab-0-Sil©" . This prod is manufactured by the Cabot Corporation, Boston, Massachuse and is generally known for its use as an anti-aggl o erati ve i various compositions, and as a general adsorbent. "Cab-0-Sil comprises colloidal, submicroscopϊc , pyrogenic silica prepar in a hot, gaseous environment by a vapor phase flame hydrolys at high temperature (around 1100°C) of a silicon compound, su as silicon tetrachl oride. It is distinct from silica gel ob¬ tained by precipitation of silicic acid from an aqueous sili- cate solution, and hardening of the precipitate. Silica gel , thus formed is internally porous, whereas "Cab-0-Sil©" has an enormous external surface area and no internal porosity. "Cab-0-Sil©" contains no water-soluble inorganic salts. It i of high chemical purity, low water content and has a high de¬ gree of particle separation. The properties and composition a grade of "Cab-0-Sil©" are listed as foTlows: Silica Content (moisture free) - 99.0 - 99.7% Free Moisture (105°C) - 0.2 - 1.5% Ignition loss at 1000°C (excluding moisture) - 0.2 - 1.0% Ca0,Mg0 - 0.00% Fe 2 0 3 +Al £ 0 3 - 0.01S Particle size range - 0.015 - 0.020 micron Surface area - 175 - 200 sq. m./gm. Specific gravity - 2.1 Color - wh te Refractive index - 1.46 pH (4% aqueous dispersion) - 3.5 - 4.2 Apparent bulk density - 2.5 - 7.0 Ibs./cu. ft. A finer grade of "Cab-0-Sil©" has the above characteristics but a particle size range of 0.007 -.0.010 micron, a surface area of substantially 325 sq. m./gm., and a refractive index of 1.46. As mentioned earlier, this form of colloidal silica may be utilized alone in solution form as the agent. In the instanc however, where it is to be disposed either within or upon a carrier or substrate, it is preferably prepared in a composit particulate form with a polyolefinic elasto eric organic bind In particular, food grade polyisobutyl ene may be utilized. In such instance, the colloidal silica is suspended in a dilu hydrocarbon solution of the elastomer, and the resulting susp sion is spread on an appropriate surface and dried to form th flake-like particles of the composite. In a preferred embodiment, the composite of the colloidal sil and the polyisobutylene is prepared in proportions of approxi mately 85% colloidal silica, 15% polyisobutyl ene, such propor tions determined by weight of the composite. This material may then be affixed by conventional procedures to a variety o substrates for further use. In the instance where certain tests of the colloidal silica w made, where the colloidal silica was incorporated within a va iety of fibrous materials which were then tested in contact w blood and bacteria on an in vitro basis, the materials ranged from rayon filament, to rayon staple, and fibers of various sizes, prepared from silica, silicic acid and fiber glass. I each instance, the colloidal silica was found to be inactive and infection proceeded unabated. By contrast, the preparation of the colloidal silica-polyiso- butylene composite offers the same activity as that of the colloidal silica alone, when disposed on, or within, a carrie or substrate. Another class of agents that is useful both for hemoglobin an red blood cells comprises anionic exchange resins such as diethyl ami noethyl cellulose (DEAE-Cell u ose) , guam * doethyl cell lose, diethyl (2-hydroxypropyl )aminoethyl dextran (QAE-Sephadex and resins capable of binding compounds having available sulfhydryl groups, such as polethyleneimine. The number of suitable anionic exchangers is large, and the foregoing listing is merely exemplary. Also, as mentioned earlier, various complex proteins may be utilized as the agent, and in addition to haptoglobin and transferrin, complex proteins such as the macromol ecu! ar binding materials known as plant lectins, may be utilized either in solution, or disposed on a substrate. . ' Lectins are known carbohydrate-binding proteins derived from plants and animals, having a wide variety of specificity. For example, Concanavalin A, a jack bean lectin, has specificity for ct-D annopyranose and α-D gl ucopyranose ; soybean lectins show spec ' ificity for α and β-D-N-acetyl gal actosa i ne and α-D- galactose units, while wheat germ lectin is specific for β-D- N-acetyl glu cosamine. Naturally, the specific complex-forming proteins " selected and utilized will vary with the nature of t organisms to be inhibited, as well as the conditions in which the organisms are found. Likewise, the agents of the present invention may be utilized individually or in mixtures, depending upon the environment in which use is contemplated. For example, one may combine a quantity of DEA-Cel 1 ul ose with "Cab-0-S 1©" for use, for example, in the treatment of surgical wounds. With respect to "Cab-0-Si !©" , the effective administration of this agent has been limited somewhat to instances where large amounts of free onovalent anion such as chloride are absent from the locus of administration. In such instances, the pre tion of the composite Cab-0-Si l©-polysi obutyl ene particles app O-.-FI to overcome this restriction, as such particles are capable of operating effectively even in the presence of physiological concentrat ons of chloride. The method of the present invention, and the operation of the agents thereof, will be better understood from a consideration of the following examples, wherein amounts of materials ex¬ pressed in percent, are intended to refer to percent by weight EXAMPLE I A large number of synthetic growth media were prepared having a low iron content. The media were thereafter inoculated with equal quantities of the bacteria E. col . Five primary group¬ ings of inocula were developed as follows: 1. Group 1 - The bacteria E. col alone. 2. Group 2 - E. coli and a small amount of hemoglobin (concentration 340 ug./ml.). 3. Group 3 - E. col i , hemoglobin, as in Group 2, above, and 1.5 x 10 -5 Molar concentration of haptoglobin purified from human plasma. _5 4. Group 4 - E. col i , a small quantity of 10 Molar he in and 2 x 10 -5 Molar concentration of haptoglobin. _5 5. Group 5 - E. coli, a quantity of 1.5 x 10 Molar concentration of haptoglobin alone. In all of the above group ngs, the volumetric quantities of hemoglobin, haptoglobin and hemin were roughly equivalent. Two batteries of such tests were performed, the first of which included all five of the above groupings; the second battery included Groups 1-3 and 5 only. All samples were maintained at a temperature of 37°C, and were observed for a period of of time ranging to about 24 hours following inoculation. At the end of the period, bacteria counts of the respective medi samples were made, and the results for the first battery of tests were tabulated and set forth in FIGURE 1, while the tes results for the second battery of tests are set forth in FIGU 2. The data from the respective groupings is identified by the corresponding graphical symbol set forth in the legends accom panying each FIGURE. The data points plotted in FIGURE 1 rep sent the respective mean and standard deviation values determ from a comparison of three samples of each grouping observed and counted at the indicated time interval. Referring to FIGURE 1, the rate of growth of the bacteria E. alone can be seen to be relatively flat, so that the initial lag phase of bacterial growth is apparent. By contrast, the addition of the hemoglobin to the growth medium alone results in a dramatic acceleration in bacterial growth. This growth, however, is neutralized in the instance of Group 3, wherein a comparable quantity of haptoglobin is introduced together with the hemoglobin, and is similar in rate to the growth pattern of the bacteria inoculated with haptoglobin alone. Finally, the results of the Group 4 media illustrates the specificity of haptoglobin for hemoglobin. In these samples, haptoglobin was introduced, however hemin, containing a varia form of available iron was provided in place of hemoglobin. Haptoglobin proved ineffective in this instance, and greatly accelerated growth of the bacteria was in evidence. The data gathered from the first battery of tests was corrobo ated by further testing, shown in FIGURE 2. In similar fashi to FIGURE 1, the edia containinc he bacteria alone exhibite relatively flat growth curve, while the media bearing the add hemoglobin exhibited a dramatic increase in the rate of bac¬ terial growth within two hours. The addition of a quantity of haptoglobin to the inoculum con taining hemoglobin, shown in Group-3, appeared to neutralize the effects of the hemoglobin, so that the bacteria exhibited a growth rate that was, in fact, even flatter than the rate o served for the bacteria alone. " Similarly, the growth rate fo Group 5, where haptoglobin alone was added, proved flatter th that of the control Group 1. The foregoing in vitro studies confirmed the specific effect that haptoglobin has upon bacterial grov/th in the presence of hemoglobin, and prompted the in vivo studies that are discuss below. EXAMPLE II In vivo studies were conducted to determine the efficacy of the present method. A total of 30 laboratory rats were divid into three groups, and were inoculated with intraper toneal in jections as set forth below. 1. Group 1 - These rats were inoculated with 2 x 10 E. col bacteria alone. g 2. Grou p 2 - T hes e rats were i nj ec ted wi t h x 1 0 E . c ol i tog et he r wi t h 1 0 g . s tro a -free h emo g l o b i n. c 3. Group 3 - These rats received 2 x 10" E. col i , 10 mg. stroma-free hemoglobin and 20 mg. purified human hapto¬ globin (the quantity of haptoglobin estimated by its binding capacity). The bacteria utilized in this test were isolated from a fatal human case of septicemia. After injection, the rets were pla under observation for a per od of 72 hours, to note the ad¬ verse effect, if any, caused by the respective injections. The rats were regularly observed during this period, and the results regarding survival were gathered and are presented in graphical form in FIGURE 3. The identity of the results of th respective groups may be determined from the legends accompany the graph. It is apparent from FIGURE 3, that the Group 1 subjects were able to successfully fend off the lethal effects of the bac¬ teria alone, as administered in the Group 1 tests. By contras however, the introduction of hemoglobin to the inoculum, resul in the death of all of the rats from overwhelming septicemia within 24 hours after injection. The inclusion of haptoglobin in Group 3 appeared to counter¬ act the lethal effects of the hemoglobin, as all of the rats n this grouping survived the entire test period. The results of this example illustrates that haptoglobin exert a neutralizing effect upon hemoglobin in the presence of bacte in an in vivo s tuation. EXAMPLE III Additional in vivo testing was conducted with laboratory rats in a manner similar to that set forth in Example II, above. Two batteries of tests were conducted, each battery differing only in the number of rats utilized, and the specific composi¬ tion of the inocula. In the first battery of tests, three groups each of seven male rats, each averaging in weight between 125 end 150 g s. , were injected with a 1.25 ml. volume of individual preparations set forth according " to croup nur.bers, below. 1. Group 1 - Inoculum comprised 20 g. stroma-free hemoglobin (SFHb) (3.4 g%), 2.5 x 10 7 E. col bacteria and 66.7 mg. Al bumiπ. 2. Group 2 - Inoculum comprised 2.5 x 10 E. coli and 86.7 mg. Al bumin, al one. 3. Group 3 - Inoculum comprised 2.5 x 10 E. col bacteria, 20 mg. stroma-free hemoglobin " (SFHb) (3.4 g%) and suffi¬ cient haptoglobin to bind 20 mg. hemoglobin (HbBC = 30 mg./ml. (equivalent to approximately 67 mg. of protein). The second battery of tests were perfor ed ^ with three groups of eight rats each, the rats otherwise identical to those utilized in the first battery of testing. The inocula utilized in the second battery of tests are set forth below. 1. Group 4 - The inoculum comprised 20 mg. stroma-free hemo- globin (SFHb) (3.4 g%), 2.5 x 10 7 E. coli bacteria and 66.7 mg. Albumin. 2. Group 5 - Inoculum comprised 2.5 x 10 E. col i and 86.6 mg. Al bumi n , al one. 3. Group 6 - Inoculum comprised 2.5 x 10 E. col bacteria, 20 mg. stroma-free hemoglobin (SFHb) (3.4 g%) and suffi¬ cient haptoglobin to bind 20 mg . hemoglobin (HbBC = 19 mg. ml. (equivalent to approximately 66.7 mg. of protein). All of the animal subjects were given intraperitoneal injections that contained hemoglobin and haptoglobin in premixture. After administration of the injections, the rats were placed under study for a period of 72 hours, and mortality of the rats was observed at 24 hour intervals. The results of this experiment are set forth in Tables I and II, and are graphically presented in FIG¬ URE 4. -17- TABLE I RAT MORTALITY AFTER- 48 HOURS GROUP NO. • MORTALITY No. . Dead Total No. Tested 1 6 7 2 1 7 3 0 7 4 6 8 5 0 8 6 0 8 TABLE II SUMMiARY - " TABLE I DATA INOCULUM MORTALITY No. Dead Total No. Tested E. coli al one 15 E. coli plus he ogl obin 12 15 E. coli, hemoglobin plus haptoglobin 0 15 A review of FIGURE 4 graphically confirms the results set for in Table II, above. The rats inoculated with either the bact alone or the bacteria containing both hemoglobin and haptoglo were generally successfully resistent to fatal infection; of total number of 30 rats tests in these two groups, only 1 rat administered E. coli alone died. By contrast, the rats to which the inoculum including E. col and hemoglobin was administered, suffered heavy mortality, wi the heaviest death rate occurring within the first 24 hours a inoculation. During th s first period, 10 out of the 15 rats died; after 48 hours 12 out of the 15 rats had died, while af 72 hours a total of 13 rats were dead. These tests further c firm the efficacy of haptoglobin in neutralizing the growth accelerating effect of hemoglobin in contact with bacteria in the peritoneal environment. EXAMPLE IV A large amount of growth media was prepared having a low iron content. The growth media comprised 5 illiliter aliquot por¬ tions of heat-inactivated human serum. Media were prepared with variant additives, and thereafter equal quantities of the bacteria were added. The media were thereafter inoculated with equal quantities of the bacteria. Four primary groupings of inocula were developed as follows: 1. Group 1 - The bacteria E. coli alone. 2. Group 2 - E. coli, Ferric ammonium citrate (FAC) (amount of 45.3ug), with or without 50 mill igra s Cab-0-Sil©. 3. Group 3 - E. col and a small amount of hemoglobin (2 mill igrams) . 4. Group 4 - E. col i , hemoglobin as in Group 3, and Cab-0-Sil (50 mill grams) . In the instance where Cab-0-Sil© and hemoglobin were both adde a pre-mixture of the two was made, so that- the hemoglobin was initially adsorbed to the Cab-0-Sil®, and the resulting adduct was then added to the growth medium. After preparation, all samples were maintained at the same temperature, and were observed for a period of time ranging up to about 24 hours following inoculation. Hourly bacterial counts were made, and have been provided, as to the first 4 hours of observation, in FIGURE 5. The data from the respective groupings is identified by the corresponding graphical symbols set forth in the legend. The data points plotted in FIGURE 5 represent the respective mean and standard deviation values determined from a comparison of 3 samples of each grouping observed and counted at the indica time interval. Referring to FIGURE 5, the rate of growth of the bacteria E. col i alone can be seen to be relatively flat, so that the ini or lag phase of bacterial growth is apparent. By contrast the addition of either the Ferric ammonium citrate (Group 2) or the hemoglobin alone (Group 3) to the growth medium result in a dramatic acceleration in bacterial growth. It is also noteworthy that Cab-0-Sil® when added to the Group 2 media, appeared to have no inhibitory effect upon bacterial growth, that the availab lity of iron from th.is synthetic source was not controlled. In Group 4, however, where both hemoglobin and Cab-0-Sil® wer added, the acceleration of bacterial growth evident with Gro.up 2 and 3 was absent and had apparently been neutralized. Thus, Group 4 exhibited a growth pattern similar in rate to that of Group 1, comprising the low-iron containing serum alone. The specificity of Cab-0-Sil© is suggested by a comparison of Groups 2 and 4. While Cab-0-Sil© appears " to be ineffective against the synthetic iron-providing compound Ferric ammonium citrate, activity is present ith respect to hemoglobin. EXAMPLE V Additional tests v/ere conducted, similar in format to those described in Example IV, above. Accordingly, similar grov/th media were preared and were inoculated with E. col i in like fashion. Four primary groupings of additive inocula v/ere de¬ veloped as follows: 1. Group 1 - The bacteria E. coli alone. 2. Group 2 - E. coli and a small amount of hemoglobin (2 milligrams). 3. Group 3 - E. coli and Cab-0-Sil© (50 milligrams). 4. Group 4 - E. col , hemoglobin as in Group 2 and Cab-0-Sil© as in Group 3. Similar conditions were observed, and the respective media were follov/ed for approximately 24 hours, with the results of first 4 hours of growth tabulated and set forth in FIGURE 6. In similar fashion to the results of FIGURE 5, the media wherei the E. coli was present alone (Group 1 ) or was present in com¬ bination with Cab-0-Sil®, the growth exhibited followed the expected lag phase pattern. By contrast, growth was greatly accelerated in the instance where hemoglobin was added (Group but was inhibited in the instance where Cab-0-Sil© was added to hemogloblin (Group 4). This last grouping exhibited a growth pattern comparable to that of Groups 1 and 3, where hemoglobin had not been added. The results of these tests confirm the conclusions reached wit respect to the tests depicted in FIGURE 5,- that Cab-0-Sil® ex¬ hibits a specific effectiveness in the sequestration of hemo¬ globin. EXAMPLE VI A specific preparation of a composite useful for coating or adsorption on solid substrates was prepared. A quantity of Cab-0-Sil© Grade K-5 and a polyisobutylene identified as Oppano Grade B-150 were combined in the ratio of 85?; Cab-0-Sil© to 15% polyiscbutyl ene. A dilute hydrocarbon of Oppanol© B-150 v/as prepared and the Cab-0-Sil was suspended therein. The suspension was thereafter cast on a flat surface and dried, and yielded a flake-like composite in which the Cab-0-Sil© particl were bound to the polyi sobutyl ene matrix. Accordingly, the present invention includes coated articles useful to dispense the blood or hemoglobin-immobilizing agents For example, fibrous materials such as rayon, cellulose fiber and others utilized in the preparation of products such as gau pads, skin bandages and the like, may be impregnated or other¬ wise coated with the agents disposed in a solution or suspensi after which the resulting coating article may be appropriately dried to volatize off any undesired vehicle. In the instance where the suspension of Cab-0-Sil© is prepared as set forth in Example VI, above, the intended suspension prior to the eva ation of the solvent, so that the resulting particles or flake may be fixed to the substrate when dry. As mentioned earlier, the present invention carries a broad spectrum of uses, going beyond the treatment of peritoneal in¬ fection. The present method and associated agents may extend to topical treatments and other personal hygiene instances whe a fluid and a bacteria are in contact with each other, and wher that fluid may contain a quantity of blood. This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restri tive, the scope of the invention being indicated by the appende claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

Claims: WHAT IS CLAIMED IS: 1. A method for arresting infection in animals in the presence of a body fluid containing iron accessible to the organisms promoting said infection, comprising administering to said in¬ fection an agent capable of immobilizing said body fluid to mak said iron unavailable to said organisms, wherein said agent is administered in an amount sufficient to make said iron com¬ pletely unavailable. 2. The method of Claim 1 wherein said agent is selected from c plexing proteins, colloidal silica, a composite of colloidal silica and a polyolefinic elastomer, cellulose-based anion ex¬ change resins, and mixtures thereof. 3. The method of Claim 2 wherein said agent comprises a com¬ plexing protein. 4. The method of Claim 3 wherein said complexing protein com¬ prises haptoglobin. 5. The method of Claim 3 wherein said complexing protein com¬ prises haptoglobin and a material selected -from the group con¬ sisting of transferrin, hemopexin and mixtures thereof. 6. The method of Claims 1-4 or 5 wherein said agent is dispose in a sterile solution. 7. The method of Claim 6 wherein said sterile solution contain from.about 1.0 to about 100 mg./nl. of said agent. 8. The method of Claims 1-4 or 5 wherein said agent is directl administered at the locus of said infection. 9. The method of Claims 1-4 or 5 wherein said agent is added to an irrigation fluid utilized at the" locus of a tissue wound 10. The method of Claims 1-4 or 5 wherein said agent is ad¬ ministered at a ratio with respect to said body fluid of up to about 3:1. 11. The method of Claim 10 wherein said ratio ranges from abou 2:1 to about 3:1. 12. The method of Claim 1 wherein said colloidal silica is pre pared from the pyrolysis of a silicon tetrahalide. 13. The method of Claims 1 or 12 wherein said composite com¬ prises a mixture of said colloidal silica and polyisobutyl ene . 14. The method of Claim 13 wherein said composite comprises 85 colloidal silica and 15% polyisobutyl ene. 15. The method of Claims 1, 12 or 14 wherein said agent is dis posed in a sterile solution. 16. The method of Claim 15 wherein said sterile solution contai from about 1.0 to about 100 mg./ml . of said agent. 17. The method of Claims 1, 12 or 15 v/herein said agent is add to an irrigation fluid utilized at the locus of a tissue wound. 18. The method of Claim 13 wherein said agent is disposed in a sterile solution. 19. The method of Claim 18 wherein said sterile solution con¬ tains from about 1.0 to about 100 mg./ml. of said agent. 20. The method of Claim 18 wherein said agent is added to an irrigation fluid utilized at the locus of a tissue wound. 21. An agent for use in arresting bacterial infections in animals in the presence of a body fluid containing iron access¬ ible to the bacteria promoting said infection, said agent se¬ lected from the group consisting of complexing proteins, anion exchange resins, a composite of colloidal silica and a polyolefinic elastomer, and mixtures thereof. 22. The agent of Claim 21 wherein said complexing protein is selected from haptoglobin, he opexin, transferrin, plant lectins specific for sugars, and mixtures thereof. 23. The agent of Claim 21 wherein said anion exchange resins comprise diethyl ami noethyl cell ul ose , guanidoethyl eel 1 ulose, diethyl (2-hydroxypropyl )aminoethyl dextran, and compounds capable of binding sulfhydryl groups, and said composite comprises colloidal silica and polyisobutyl ene. 24. The agent of Claim 23 wherein said agent comprises a mix¬ ture of diethyl aminoethyl cell ulose and colloidal silica. 25. The agent of Claim 23 wherein said agent comprises said composite alone. 26. The agent of either Claims 23 or 25 wherein said com¬ posite contains 85% colloidal silica and 15% polyisobutylene. 27. An appliance for use in arresting bacterial infection comprising an absorbent substrate having at least a portion of its effective surface area coated with the agent of Claims 22, 23 or 24. OMPI 28. An appliance for use in arresting bacterial infection comprising an absorbent substrate having at least a portion of its effective surface area coated with the agent of Claim 29. The appliance of Claim 27 wherein said absorbent substra is selected from surgical sponges, bandages, gauze, sanitary napkins, and tampons. 30. The appliance of Claim 28 wherein said absorbent sub- strate is selected from surgical sponges, bandages, gauze, sanitary napkins, and tampons.

Inventors: CERAMI ANTHONY
Applicants: EVREKA INC
Application year: 1982
Main classification: A61K31
IPC codes: A61F13, A61K31, A61K33, A61K38, A61L15, A61P31